Assessing Predictive Performance of Fibrosis-4 Index in Settings With Lower Prevalence of Liver Fibrosis.

Clinical guidelines for screening for liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) commonly recommend use of the Fibrosis-4 (FIB-4) index as a first-line test, followed by subsequent testing and referral for FIB-4 ≥1.30.Recently, pharmacological interventions have received regulatory approval in the United States (U.S.) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults, including resmetirom (Rezdiffra) and semaglutide (Wegovy). Consequently, it is of particular importance that screening effectively identify patients with moderate-to-advanced (F2-F3) liver fibrosis who may be candidates for treatment.